Adma Biologics, INC Schedule 13G passive stakes

State Street Corporation and SSGA Funds Management, Inc. have updated their beneficial ownership filing for ADMA Biologics Inc., reporting a combined 7.4% stake.

Vanguard Capital Management has reported beneficial ownership of 12,110,153 shares, representing 5.08% of the outstanding common stock of ADMA Biologics Inc.

The Vanguard Group reports 0% beneficial ownership in ADMA Biologics Inc. following an internal realignment.

Invesco Ltd. has reported a 5.0% beneficial ownership stake in ADMA Biologics Inc., holding 11,785,202 shares of common stock.

State Street Corporation has reported a 5.1% beneficial ownership stake in ADMA Biologics Inc., signaling significant institutional interest.

The Vanguard Group has reported a significant beneficial ownership stake of 8.94% in ADMA Biologics Inc., totaling over 21 million shares.

State Street Corporation has filed a Schedule 13G, reporting a 4.8% passive beneficial ownership stake in ADMA Biologics Inc. as of March 31, 2025.

Invesco Ltd. has filed a Schedule 13G, revealing a beneficial ownership of 5.4% of ADMA Biologics Inc.'s common stock, held for investment purposes.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 15.1% beneficial ownership stake in ADMA Biologics, Inc. as of March 31, 2025.

Invesco Ltd. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.8% in ADMA Biologics Inc. as of December 31, 2024.